Kyushu Communication: Subsidiary's procyclidine hydrochloride injection obtains drug registration certificate

Kyushu Communication announced on December 26th that on December 25, 2025, its subsidiary Beijing Jingfeng Pharmaceutical Group Co., Ltd. received the "Drug Registration Certificate" for the approval and issuance of the Injection of Isopropyl Chlorpromazine by the National Medical Products Administration. The Isopropyl Chlorpromazine injection is an antihistamine drug, suitable for allergies of the skin or mucous membranes, motion sickness, adjuvant therapy before and after anesthesia and surgery, and prevention and treatment of radiation-induced or drug-induced nausea and vomiting. As of the date of this announcement, Huixueyuan has invested approximately 4.67 million yuan in research and development expenses for this drug.